RT @OncBrothers@twitter.com
3 new drugs/indications were approved by @FDAOncology@twitter.com for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary!
- #TDXd x 2
- #Olaparib
- #Pembrolizumab
- #Mirvetuximab
#bcsm #gynsm @OncoAlert@twitter.com #breastcancer #MedTwitter #OncEd #MedEd #ovariancancer
🐦🔗: https://twitter.com/OncBrothers/status/1607753014521262081
#tdxd #olaparib #pembrolizumab #Mirvetuximab #bcsm #GYNSM #breastcancer #medtwitter #OncEd #MedEd #ovariancancer
#HER2low brain Mets data with #TDXd
RT @drsarahsam@twitter.com
First results of intracranial activity in HER2Low Brain Metastases with T-DXd. Small study, but 33% intracranial response rate #bcsm
🐦🔗: https://twitter.com/drsarahsam/status/1600633158994632706